This study is testing a new medication called INS018_055 for people with Idiopathic Pulmonary Fibrosis (IPF). IPF is a serious lung disease that makes it hard to breathe. Current treatments can have side effects, so researchers are looking for new options. INS018_055 works by targeting a specific protein called RAF. In this study, some participants will receive INS018_055 as a tablet, and others will receive a placebo (an inactive tablet). The main goal is to see how safe INS018_055 is over 12 weeks by tracking any side effects. You may be able to join if you are at least 40 years old and have a diagnosis of IPF. The study is currently unclear on its recruitment status.

Study design

This interventional study plans to enroll 40 participants. It compares INS018_055 tablets to placebo tablets.

What's involved

You would take either INS018_055 or a placebo tablet. Your safety will be monitored from Day 1 up to Week 12.

Compensation

Not stated in the trial record.

Follow-up

Your safety will be monitored up to Week 12 (End of Treatment).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.